Renier Brentjens, a CAR T-cell pioneer, views armored CAR T-cells as a promising avenue for treating solid tumors and ...

A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science of addressing critical issues with CAR T cell therapy in patients with ...

A new article outlines a new tool that measures blood inflammation as a marker for poor CAR T therapy outcomes.

A review of the side effects of CAR T-cell therapy, including CRS, ICANS, tumor lysis syndrome, and late-onset toxicities, and management strategies.

Researchers from the City of Hope and Memorial Sloan Kettering (MSK) Cancer Center, US, have developed a tool named ...

Cancer Center have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) patient's likely response ...

Researchers with City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United ...

A multi-institutional team led by The University of Osaka developed a chimeric antigen receptor (CAR) T cell-based strategy ...

A study conducted by Prof. Thai-Yen Ling at National Taiwan University underscores the potential of small extracellular ...

Discover Nkarta's groundbreaking cell therapy advancements, robust financials, and investment potential. Click here to read ...